Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 142300.0
(1.14%)
KRW 142300.0
(1.14%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 9.55 Billion KRW | -23.23% |
| 2022 | 12.56 Billion KRW | 182.21% |
| 2021 | -15.28 Billion KRW | -502.07% |
| 2020 | 3.8 Billion KRW | -84.03% |
| 2019 | 23.8 Billion KRW | 66.46% |
| 2018 | 14.3 Billion KRW | -37.84% |
| 2017 | 23 Billion KRW | -5.54% |
| 2016 | 24.35 Billion KRW | 17.25% |
| 2015 | 20.77 Billion KRW | 9.67% |
| 2014 | 18.94 Billion KRW | 19.46% |
| 2013 | 15.85 Billion KRW | 190.46% |
| 2012 | 5.45 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.13 Billion KRW | 58.24% |
| 2024 Q1 | 1.86 Billion KRW | -10.62% |
| 2023 Q3 | 2.38 Billion KRW | -26.5% |
| 2023 Q4 | 2.08 Billion KRW | -12.55% |
| 2023 FY | 9.64 Billion KRW | -23.23% |
| 2023 Q1 | 1.84 Billion KRW | 1.12% |
| 2023 Q2 | 3.24 Billion KRW | 75.56% |
| 2022 FY | 12.56 Billion KRW | 182.21% |
| 2022 Q1 | 3.59 Billion KRW | 2525.14% |
| 2022 Q2 | 3.39 Billion KRW | -5.61% |
| 2022 Q3 | 3.74 Billion KRW | 10.29% |
| 2022 Q4 | 1.82 Billion KRW | -51.23% |
| 2021 Q3 | -8.9 Billion KRW | -424.46% |
| 2021 Q1 | -4.53 Billion KRW | -76.43% |
| 2021 Q2 | -1.69 Billion KRW | 62.57% |
| 2021 Q4 | -148.38 Million KRW | 98.33% |
| 2021 FY | -15.28 Billion KRW | -502.07% |
| 2020 Q2 | 3.67 Billion KRW | -5.85% |
| 2020 FY | 3.8 Billion KRW | -84.03% |
| 2020 Q4 | -2.57 Billion KRW | -268.74% |
| 2020 Q3 | -697.39 Million KRW | -118.98% |
| 2020 Q1 | 3.9 Billion KRW | 737.21% |
| 2019 Q2 | 8.54 Billion KRW | 25.53% |
| 2019 Q1 | 6.8 Billion KRW | 287.29% |
| 2019 FY | 23.8 Billion KRW | 66.46% |
| 2019 Q4 | -612.32 Million KRW | -105.85% |
| 2019 Q3 | 10.47 Billion KRW | 22.59% |
| 2018 Q2 | 7.14 Billion KRW | 25.82% |
| 2018 Q3 | 6.3 Billion KRW | -11.77% |
| 2018 Q4 | -3.63 Billion KRW | -157.62% |
| 2018 FY | 14.3 Billion KRW | -37.84% |
| 2018 Q1 | 5.68 Billion KRW | 30.54% |
| 2017 Q1 | 7.06 Billion KRW | 14.98% |
| 2017 FY | 23 Billion KRW | -5.54% |
| 2017 Q4 | 4.35 Billion KRW | -43.5% |
| 2017 Q2 | 4.84 Billion KRW | -31.44% |
| 2017 Q3 | 7.7 Billion KRW | 58.93% |
| 2016 FY | 24.35 Billion KRW | 17.25% |
| 2016 Q3 | 6.29 Billion KRW | 0.98% |
| 2016 Q4 | 6.14 Billion KRW | -2.35% |
| 2016 Q2 | 6.23 Billion KRW | 9.78% |
| 2016 Q1 | 5.67 Billion KRW | 3.9% |
| 2015 FY | 20.77 Billion KRW | 9.67% |
| 2015 Q3 | 5.71 Billion KRW | 20.43% |
| 2015 Q4 | 5.46 Billion KRW | -4.31% |
| 2015 Q2 | 4.74 Billion KRW | -2.24% |
| 2015 Q1 | 4.85 Billion KRW | 12.26% |
| 2014 Q2 | 4.58 Billion KRW | -12.63% |
| 2014 Q1 | 5.24 Billion KRW | 35.76% |
| 2014 FY | 18.94 Billion KRW | 19.46% |
| 2014 Q4 | 4.32 Billion KRW | -9.81% |
| 2014 Q3 | 4.79 Billion KRW | 4.56% |
| 2013 Q2 | 3.78 Billion KRW | 10.24% |
| 2013 Q3 | 4.78 Billion KRW | 26.42% |
| 2013 Q1 | 3.43 Billion KRW | 0.0% |
| 2013 Q4 | 3.86 Billion KRW | -19.18% |
| 2013 FY | 15.85 Billion KRW | 190.46% |
| 2012 FY | 5.45 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | -9.78 Billion KRW | 197.697% |
| ST Pharm Co.,Ltd. | 31.03 Billion KRW | 69.197% |
| ABL Bio Inc. | -27.32 Million KRW | 35089.552% |
| Cellid, Co., Ltd. | -12.19 Billion KRW | 178.372% |